On July 13, 2020 iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), reported financial results for the quarter ended March 31, 2020 (Press release, iCo Therapeutics, JUL 13, 2020, View Source [SID1234562021]). Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Stated William Jarosz, CEO of iCo Therapeutics Inc., "We were pleased with the positive outcome from our Phase 1b study of our oral Amphotericin B asset during the quarter and that we were able to complete the study with encouraging results and minimal disruption given the current Covid-19 pandemic. On iCo-008, we continue to work closely with our partner Alexion in advancing the program."
Q1 2020 Operational and Financial Highlights
In January 2020, the assignment of the IMMUNE sublicense to Alexion was completed. Under the terms of the assignment, Alexion was required to pay US$6 million into the Court in the settlement of IMMUNE’s creditor claims in exchange for IMMUNE’s rights under the IMMUNE License Agreement.
On February 25, 2020 we announced the successful completion of our Phase 1b study with no serious adverse events. On April 15, 2020, we announced the pharmacokinetic data from this study which showed a doubling in the AUC (0-inf), a measure of drug accumulation, after 10 days dosing compared to day 1 dosing.
On March 9, 2020 Andrew Rae, MBA, resigned from his roles as both President & CEO and Director. Ms. Susan Koppy, a member of iCo’s board of directors since 2015, assumed the role of President and Mr William Jarosz, a member of iCo’s board of directors since 2006, assumed the role of CEO.
Financial results for Quarter ended March 31, 2020
We incurred a total comprehensive loss of $ 645,570 for the quarter ended March 31, 2020 compared to a total comprehensive loss of $353,680 for the quarter ended March 31, 2019, representing an increased loss of $291,890. The increase in the loss is primarily the result of higher research and development expenses offset by lower general and administrative expenses and higher research and development tax credits recognized in Q1 2020.
Research and development expenses were $670,690 for the quarter ended March 31, 2020 compared to $85,095 for the quarter ended March 31, 2019, representing an increase of $585,595. The increase related to higher contract research expenses for clinical trials conducted on the Oral Amp B program in the quarter ended March 31, 2020.
The Phase 1b study was conducted in Australia, which provides refundable tax credits for qualifying research and development activities conducted there. The refundable tax credit is calculated at 43.5% of the qualifying expenditures and the Company recognized $238,258 in other income as its estimate of the tax refund related to qualifying expenditures for the quarter ended March 31, 2020.
For the quarter ended March 31, 2020 general and administrative expenses were $216,436 compared to $278,767 for the quarter ended March 31, 2019, representing a decrease of $62,331. The decrease reflects lower professional fees during the period. The Company’s participation in the IMMUNE bankruptcy process last year caused an increase in professional fees in the corresponding quarter of the prior year.
Liquidity and Outstanding Share Capital
As at March 31, 2020, we had cash and cash equivalents of $479,005 compared to $989,937 as at December 31, 2019.
As at July 13th, 2020, we had an unlimited number of authorized common shares with 153,747,713 common shares issued and outstanding.